TP53 and neoplasm: Our model helps explain how tumor-derived p53 mutants promote, rather than suppress HR (Bertrand et al., 1997; Saintigny et al., 1999; Saintigny and Lopez, 2002; Linke et al., 2003), although the CTD of tumor-derived p53 mutants remain intact and are capable of interacting with Rad51.